SSY GROUP (02005) reported profit attributable to shareholders of approximately HK$460 million for the first three quarters, up 15.5% year-on-year.

SSY GROUP (02005) announced that the Group's unaudited revenue for the nine months ended September 30, 2026 was approximately HK$3.52 billion (same period in 2025: approximately HK$3.102 billion), up 13.5% year-on-year, mainly due to the recovery in growth of the Group's intravenous infusion and active pharmaceutical ingredient businesses. The Group's unaudited gross profit for the nine months ended September 30, 2026 was approximately HK$1.442 billion (same period in 2025: approximately HK$1.294 billion), up 11.4% year-on-year, with an unaudited gross profit margin of approximately 41.0%, down 0.7 percentage points year-on-year. For the nine months ended September 30, 2026, the Group's unaudited profit attributable to shareholders of the Company was approximately HK$460 million, up 15.5% year-on-year (same period in 2025: approximately HK$399 million).